Direct discovery · Medicine · Biology · Chemistry
AI-discovered rentosertib reaches a randomized phase 2a trial
An AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis tested in a randomized phase 2a trial.
Summary
Nature Medicine reports a randomized phase 2a trial of rentosertib, a generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis. In 71 patients over 12 weeks, treatment-emergent adverse events were similar across arms and the highest dose showed an increase in forced vital capacity; the authors call for larger trials.
AI role
Contributed to target and molecule discovery before the candidate advanced into human efficacy testing.
Narrative role
This is a milestone because it moves AI drug-discovery evidence from preclinical screening into peer-reviewed human clinical research.
Caveat
The authors call for larger trials; phase 2a evidence is not proof of approved therapeutic impact.